Antibody-based drug helps 'bridge' leukemia patients to curative treatment
In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia (ALL) whose disease had relapsed following standard therapies, qualified ...
Jun 12, 2016
0
3